Uveal
melanoma is the
most common primary malignant tumour of intraocular malignancy, arises from
melanocytes in the iris, and ciliary body. The most common symptoms of uveal
carcinoma include blurred vision, photopsia, visual field loss, visible tumour,
pain, and metamorphopsia.
The
management of uveal melanoma can be divided into globe-preserving therapy or
enucleation. Globe-preserving therapies can broadly classified into radiation,
surgical, and laser therapy. The drug candidates of uveal melanoma disease
pipeline include, but not limited to, nivolumab and IMCgp100. Some of the
companies having drugs in the uveal melanoma therapeutics pipeline includes
Harmonic Pharma, Immunocore Ltd. and Celldex Therapeutics, Inc.
Request
to Get the Sample Pages at:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations, collaborations,
licensing, grants, technology, and others.
No comments:
Post a Comment